China Hydrocephalus Market Size: Strategic Industry Outlook

China Hydrocephalus Market Overview

The China hydrocephalus market is expected to register a CAGR of 5.2%, exceeding the global average growth rate of 3.9% over the forecast period. Faster growth reflects a combination of demographic pressure, improving neurosurgical capacity, and gradual expansion of access to pediatric and neurological care across urban healthcare systems.

While the global hydrocephalus market remains driven by steady procedure volumes, China represents a relatively higher-growth environment, supported by structural healthcare developments rather than short-term demand fluctuations.In China, a total of 44,932 hydrocephalus shunting procedures were performed in 2025, of which revision hydrocephalus shunt procedures was carried out in 73% cases.

Hydrocephalus Care Scenario in China

China reports a large pediatric population base, alongside an expanding elderly population vulnerable to conditions such as normal pressure hydrocephalus. Urban tertiary hospitals increasingly serve as referral centers for neurological disorders, leading to higher diagnosis and surgical intervention rates compared to previous decades.

Improvements in:

• Prenatal screening
• Neonatal intensive care
• Pediatric neurosurgery infrastructure

have contributed to earlier detection and treatment initiation in major metropolitan regions. However, access remains uneven across rural and lower-tier cities, creating a mixed landscape of advanced care clusters alongside underpenetrated regions.

Growth Drivers Supporting Above-Global CAGR

Several structural factors support China’s higher-than-global growth trajectory:

• Large untreated and newly diagnosed patient pool: Congenital hydrocephalus alone creates a steady annual inflow of new cases. Population-based birth-defect surveillance studies in China report congenital hydrocephalus prevalence around 7 per 10,000 births.
• Ongoing investment in tertiary hospital infrastructure: China’s hospital base has expanded materially over time. As per the estimates there were 19,712 hospitals in 2008 rising to 36,976 hospitals by end of 2022, alongside 8.748 million medical personnel in hospitals.
• Expansion of medical device availability through public procurement systems: China’s centralized/bulk procurement approach has been expanding across medical consumables categories, which can directly shape device pricing and availability in public hospitals.
• Rising clinical awareness of hydrocephalus as a treatable neurological condition

These factors collectively position China as a key growth contributor within the broader hydrocephalus market landscape.

Major Players in the China Hydrocephalus Shunt Market

The China hydrocephalus shunt systems market is highly competitive and concentrated, with a mix of global multinationals and other medical device manufacturers offering shunt products such as valves, catheters, and accessories.